At first glance, the companies may seem very similar. Not only did they develop the first two COVID vaccines authorized by the Food and Drug Administration, they used messenger RNA (mRNA). It's a set of genetic instructions that direct cells to make proteins that trigger an immune response training your body for any future encounter. The technology had never been approved for a vaccine in humans.
Yet, dig a little deeper and Moderna (NASDAQ: MRNA) and BioNTech (NASDAQ: BNTX) differ in important ways. They began differently, they are managed differently, and the path they are taking post-COVID is also diverging. So which one will make a better investment? A few clues offer a possible answer.
Image source: Getty Images.
For further details see:
Better Biotech Stock: Moderna vs. BioNTech